1916

Commonwealth Serum Laboratories (CSL) is established to service the health needs of an infant Australian nation.

1916

1919

When the deadly Spanish influenza pandemic strikes Australia, CSL responds rapidly with 3 million doses of a mixed bacterial vaccine.

1919

1930

CSL releases a tiger snake antivenom, and goes on to develop antivenoms for Australia’s most venomous creatures.

1930

1942

Production commences on an influenza virus vaccine and the first 1 million doses are supplied to Australian and British troops.

1942

1951

WHO designates CSL as a Influenza Reference Laboratory to enhance Southern Hemisphere influenza surveillance.

1951

1957-8

CSL responds quickly to the Asian influenza pandemic, producing 1.6 million doses of vaccine.

1957

1968-9

As the Hong Kong influenza pandemic emerges, CSL produces 5 million doses of vaccine to protect the region.

1968

1992

WHO designates CSL as an Influenza Collaborating Centre, strengthening its role in the global influenza network.

1992

1994

CSL becomes a private company.

1994

2002

CSL extends its influenza vaccine supply into the Northern Hemisphere.

2002

2009

The organisation's rapid response to the H1N1 (swine flu) pandemic sees Australia become one of the first countries in the world to roll-out vaccine to its population, with stocks also donated to the WHO.

2009

2015

Seqirus, one of the largest influenza vaccine manufacturers in the world, is created when CSL acquires the Novartis' influenza vaccine business, combining it with bioCSL.

2015

2016

Seqirus launches three new products and is well positioned for the future.

2016

2018

Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process.

2018